Buclizine-dihydrochloride-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBuclizine dihydrochlorideCat. No.: HY-A0128ACAS No.: 129-74-8分式: CHClN分量: 505.95作靶點(diǎn): Histamine Receptor作通路: GPCR/G Protein; Immunology/Inflammation; NeuronalSignaling儲(chǔ)存式: 4C, sealed storage, away from moisture* In solvent : -80C

2、, 6 months; -20C, 1 month (sealedstorage, away from moisture)溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 2.5 mg/mL (4.94 mM; Need ultrasonic)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.9765 mL 9.8824 mL 19.7648 mL5 mM - - -10 mM - - -請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Buclizine dihydro

3、chloride具有服活性的抗組胺、抗過(guò)敏化合物。Buclizine dihydrochloride 對(duì)種強(qiáng)效的致畸劑。體外研究Buclizine (0-100 M, 72 h) inhibits cancer cell growth by binding to TCTP and induction of cell differentiation3.Cell Proliferation Assay 3.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemECell Line: MCF-7 cells 3.Concentration: 0-100 M.

4、Incubation Time: 72 h.Result: The IC50 was 19.18 5.32 M.體內(nèi)研究 Buclizine dihydrochloride (40 mg/kg) exhibits teratogenic effect 1.Buclizine dihydrochloride exhibits the t1/2 of 10 h via oral administration 2.Animal Model: Eighty-seven mature female rats weighing 24020 grams 1.Dosage: 30-200 mg/kg.Admi

5、nistration: From days 10 to 15.Result: Exhibits teratogenic effect dose-dependently when 40 mg/kg.REFERENCES1. C T King, et al. Teratogenic effect of buclizine and hydroxyzine in the rat and chlorcyclizine in the mouse. Am J Obstet Gynecol. 1966May 1;95(1):109-11.2. Nawab Sher, et al. Simultaneous d

6、etermination of antihistamine anti-allergic drugs, cetirizine, domperidone, chlorphenamine maleate,loratadine, meclizine and buclizine in pharmaceutical formulations, human serum and pharmacokinetics application. Analytical methods March 2014.3. Ean-Jeong Seo, et al. Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approachfor differentiation therapy. Oncotarget . 2016 Mar 29;7(13):16818-39.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only